Scarica l'app Stockscreener
82.76
0.06%
-0.05
Dopo l'orario di chiusura:
83.01
0.25
+0.30%
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
FY2024 EPS Estimates for Belite Bio Lowered by HC Wainwright - Defense World
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 13.5% in October - MarketBeat
Belite Bio (NASDAQ:BLTE) Given New $110.00 Price Target at Maxim Group - MarketBeat
Belite Bio stock soars to all-time high of $84.2 amid robust gains - Investing.com UK
Earnings call: Belite Bio reports progress in Tinlarebant trials By Investing.com - Investing.com Australia
Belite Bio shares target boosted, retains buy rating on trial progress - Investing.com
Earnings call: Belite Bio reports progress in Tinlarebant trials - Investing.com
Belite Bio Advances in Retinal Disease Trials - TipRanks
Belite Bio Advances in Tinlarebant Trials, Appoints New CMO - TipRanks
Belite Bio Advances Eye Disease Trials, Posts $109M Cash Position in Q3 Update | BLTE Stock News - StockTitan
Riot Platforms Inc (RIOT-Q) QuotePress Release - The Globe and Mail
Belite Bio (BLTE) Set to Announce Earnings on Tuesday - MarketBeat
Belite Bio (BLTE) Sets Q3 2024 Earnings Call: Key Updates on Retinal Disease Pipeline | BLTE Stock News - StockTitan
Belite Bio stock soars to all-time high of $70.4 amid robust growth - Investing.com
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Belite Bio Offers New Warrant Opportunities to Investors - TipRanks
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds - ForexTV.com
Nike Inc (NKE-N) QuotePress Release - The Globe and Mail
Belite Bio stock soars to all-time high of $67.6 amid robust gains - Investing.com UK
TSX Smallcap Index (TXTW) QuotePress Release - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Hits New 52-Week HighHere's What Happened - MarketBeat
Belite Bio (NASDAQ:BLTE) Trading Up 4%Should You Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Hits New 12-Month HighHere's Why - MarketBeat
Belite Bio stock soars to all-time high of $56.62 By Investing.com - Investing.com UK
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting - The Bakersfield Californian
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial - Ophthalmology Times
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighStill a Buy? - MarketBeat
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit - The Bakersfield Californian
Week in ReviewOctober 5, 2024 - Ophthalmology Times
Belite Bio (NASDAQ:BLTE) Hits New 1-Year High at $50.69 - MarketBeat
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire
Armistice Capital LLC Invests $6.76 Million in Belite Bio, Inc (NASDAQ:BLTE) - MarketBeat
Servicenow Inc (NOW-N) QuotePress Release - The Globe and Mail
International companies to host live webcasts at Deutsche - GlobeNewswire
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 5.1% in August - MarketBeat
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - GlobeNewswire Inc.
Belite Bio (NASDAQ:BLTE) Rating Reiterated by HC Wainwright - Defense World
Belite Bio shares hold buy rating, steady target on trial progress - Investing.com
Belite Bio's (BLTE) Buy Rating Reiterated at HC Wainwright - MarketBeat
Belite Bio Announces First Patient Dosed in Phase 2/3 - GlobeNewswire
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease - StockTitan
Belite Bio Welcomes New Chief Medical Officer - TipRanks
Belite Bio to Participate in Three Upcoming Investor Conferences - StockTitan
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.6% in August - MarketBeat
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer - ForexTV.com
Belite Bio (NASDAQ:BLTE) Sees Large Volume Increase - MarketBeat
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Expands By 10.7% - MarketBeat
Belite Bio (NASDAQ:BLTE) Trading Down 1.8% - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for Belite Bio, Inc (NASDAQ:BLTE) - Defense World
FY2024 EPS Estimates for Belite Bio, Inc Lowered by Analyst (NASDAQ:BLTE) - Defense World
Golden Ocean Group (NASDAQ:GOGL) Downgraded to Sell at StockNews.com - Defense World
Abtech (OTCMKTS:ABHD) Shares Cross Above 50 Day Moving Average of $1.08 - Defense World
Cambian Group (LON:CMBN) Stock Price Crosses Below Two Hundred Day Moving Average of $192.40 - Defense World
Leerink Partnrs Equities Analysts Cut Earnings Estimates for Belite Bio, Inc (NASDAQ:BLTE) - Defense World
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):